Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Hot Investor Mandate: Investment Firm Partnered with Family Office Invests in Early-Stage Therapeutics, Devices, Diagnostics Companies Across the USA

4 Feb

A firm dedicated to accelerating the growth of seed-stage life sciences companies operates in partnership with a USA-based family office. The firm invests $250-500K in early financing rounds within high-quality syndicates. The firm invests in companies based in the U.S.

The firm is seeking investments in next-generation therapeutics, medical device, and diagnostics companies. Within the therapeutics sector, the firm invests in cell, gene, oligonucleotide, and microbial therapies, as well as other targeted therapies for well-defined diseases. Typical investments occur at the stage of lead optimization and IND-enabling studies. Within MedTech, the firm invests in platforms leveraging novel biological insights, including cellular and molecular diagnostics, biomaterials, and bio-active implants. Typical investment stage is during late-stage product development approaching regulatory clearance and commercialization.

The firm does not have any specific company or management team requirements. The firm is a strategic as well as financial investor, helping companies develop relationships and accelerate growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Family Office Actively Seeking Medical Device & Diagnostics Investment Opportunities, as well as AI-Related Technologies

4 Feb

A family office based in the USA looks to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers company that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Life Science Nation’s 2021 Partnering Theme: Bigger and Better

28 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is ramping up its partnering theme for 2021 by emphasizing global roadshow preparation for the 4,500 fundraising CEOs and scientist-entrepreneurs at our cross-border, cross-domain, digital partnering events. LSN’s infrastructure is designed to help early-stage companies prepare for the capital and partnering journey with products and services including, but not limited to:

  • Two databases: Investor Platform with 10,000 global investors and strategic partners, and Company Platform with 60,000 life science companies.
  • 300+ university, regional, and governmental tech hubs that use LSN partnering events to help their local technology companies get global exposure.
  • Growing global super-structure consisting of a cross-border, cross-domain, two-way bridge for licensing and funding life science technology assets.
  • Quarterly Healthtech Partnering Week (HPW), consisting of three partnering conferences: RESI, 4D Meets AI, and Longevity, Health & Innovation (co-organized with Mary Furlong & Associates), that further develops our global footprint as a major force in connecting buyers and sellers in the international arena.
  • Focus on Cures Accelerator for sourcing, vetting, developing and preparing key companies for global licensing and fundraising campaigns.
  • I-Bank, Boston Innovation Capital, for licensing and funding campaigns for elite healthcare technology companies internationally.

LSN has invested 8 years in building out this global network, and our 2021 growth will serve as a compass toward the future. We look forward to developing our products, services, as well as deep alliances with the global players leveraging this unique golden age of life science, where breakthrough and game-changing technology is in no short supply.

 

Join the Healthtech Partnering Week Agenda

28 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Life Science Nation (LSN)’s Healthtech Partnering Week, March 15-19, 2021, has announced its agenda, and we hope you’ll consider taking part! Whether you are a fundraising CEO, scientist-entrepreneur, service provider, regional tech hub, or investor, there are ways to get involved and take advantage of the weeklong partnering event by attending, speaking, pitching, sponsoring, or exhibiting.

Investors

Digital Redefining Early Stage Investments (RESI) is a powerful gathering focused on early-stage funding across all verticals of life science. One of its strongest connection tools is its live investor panels offering insights into the early-stage fundraising process. If you’re an investor working with companies developing cutting edge biotech, medtech, and healthtech advancing the power and potential of healthcare and medicine, apply to join a panel at RESI.

4D Meets AI is hosting panels where active investors are joined by their portfolio companies to discuss funding, partnerships, and the future of AI in life science and healthcare. Join us for four live panels, each delving into one of the 4Ds: drugs, devices, diagnostics, and digital health. If you’re an investor in AI in healthcare and have a portfolio company to highlight, apply to participate on a 4D Meets AI panel.

Investors seeking opportunities in age-tech and longevity is a powerful and growing community. If you work with companies developing technology to advance Senior Care, Cardiovascular Disease, Oncology, Central Nervous System (CNS) Disease, Diabetes, Chronic Respiratory Disease (CRD), Hearing Loss & Sight Deterioration, Arthritis, or Mental Health Conditions, apply to join the conversation at Longevity, Health & Innovation.

Early-Stage Companies

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies actively raising seed capital (25K-2MM), Series A (2MM-10MM), or Series B (10MM-50MM) to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Companies can learn more and apply for each Healthtech Partnering Week conference:

Tech Hubs

Tech hubs are invited to offer constituents to participate in Healthtech Partnering Week with special offers specifically for them. Constituents can save 50% on registration and receive a free dedicated landing page for optimal exposure on the conference Live Agenda. Additionally, LSN hosts partnering webinars to help CEOs make strong connections with 350+ healthcare investors, including a training workshop to help CEOs seeking financing to move their technologies forward in the development process.

Service Providers & Strategic Partners

Sponsorship helps companies gain visibility in the early-stage life science community by leveraging our close-knit network of key decision-makers to make promising connections. If you fall into any of these categories, LSN’s Business Development team would like to connect to share how Healthtech Partnering Week can help you meet your goals:

  • Global investors, channel partners, strategic partners and big pharma sourcing technology assets for their pipeline, channels and new silos
  • Service providers selling their services to funded CEOs, establishing relationships with global strategic partners and expanding market presence.
  • Investors expanding their portfolio through technology assets, finding investment partners for joint deal syndication, and finding service providers to help develop their portfolio.

View our complete offerings in the Sponsorship Brochure and let us know how our dedicated team can add value to your sponsorship experience.

Announcing Healthtech Partnering Week, March 15-19, 2021

21 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is pleased to announce the next Healthtech Partnering Week takes place March 15-19, 2021. Super early bird registrations save $100 when they sign up by January 29!

Healthtech Partnering Week is an early-stage fundraising vessel, featuring three back-to-back digital partnering conferences: Redefining Early Stage Investments (RESI), 4D Meets AI, and Longevity, Health & Innovation (LHI), which is co-organized with Mary Furlong & Associates. The previous Healthtech Partnering Week, held in conjuncture with J.P. Morgan’s virtual Health Care Conference, hosted 20 panels, 10 live pitch sessions, 2,000+ meetings, and welcomed 600+ investors actively seeking opportunities in healthcare and life science.

Each conference is designed for early-stage fundraising executives to reach potential partners based on product fit and stage of development. Many have begun relationships that have led to millions invested. LSN is proud to be a regular part of the early-stage fundraising ecosystem within life science and healthcare and invites you to join us in March!

Learn More at www.healthtechpartneringweek.com.

Innovator’s Pitch Challenge Applications Open at LSN Healthtech Partnering Week

21 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN)’s Healthtech Partnering Week serves as a vehicle for early-stage fundraising within life science and healthcare with many valuable features, including a match-based partnering system and hours of educational materials like entrepreneur bootcamps, branding workshops, and investor panels. However, one of the most powerful additions to the digital partnering space is the Innovator’s Pitch Challenge (IPC).

The IPC highlights exceptional early-stage companies and provides them the opportunity to pitch live to a panel of investor judges. Accepted companies submit pitching materials, including a pitch deck, executive summary, and a long-form pitch video that are sent to judges to review prior to live Q&A sessions. During the live session, each company will present a brief elevator pitch and participate in a Q&A from the judges and audience.

IPC applications are open until Friday, February 19th. Accepted applicants who sign up before Friday, January 29 will also save $100 on registration. Learn more about the IPC and how it can help boost your exposure and increase visibility to hundreds of investors and strategic partners!

Congratulations to Digital RESI January Innovator’s Pitch Challenge Winners!

14 Jan

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital Redefining Early-Stage Investments (RESI) January Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovator’s Pitch Challenge (IPC). Each participating finalist company had a dedicated page featuring a short pitch, executive summary, and other supplementary materials available for viewing.

The Digital RESI January Live Agenda is open to registered attendees until February 13, so there’s still time to check out the Digital RESI January Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!

The RESI Team would like to thank every IPC company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!

First Place: Concarlo Holdings

Concarlo Holdings, LLC is a precision medicine company focusing on unmet needs in oncology: developing therapeutics and diagnostics to extend the lives of cancer patients, beginning with women with metastatic breast cancer.

Check Concarlo Holdings’ Dedicated Page

 

Tied for Second Place: BCell Solutions

BCell Solutions, Inc., is a pre-clinical biopharmaceutical company commercializing a family of highly anti-inflammatory, small molecule peptides. Uses include treatment of chronic inflammation, acute/hyper-inflammation, and neuroinflammation. Our lead indication is kidney disease, supported by data from two animal models showing BCS Immunotherapy’s successful reversal of loss of kidney autoregulatory function, a key element of chronic kidney disease and renal failure.

Check BCell Solutions’ Dedicated Page

 

Tied for Second Place: Surgical Innovation Associates

Surgical Innovation Associates (SIA) is a Chicago-based medical device spin-out from Northwestern University with FDA 510(k) clearance, CE Mark, and rapidly growing sales for its first product, DuraSorb™ – a patented absorbable surgical mesh in the $1B+ general and reconstructive surgery market. In only a few months on the market, we have grown sales to >$100k/month at >80% gross profit margin. SIA is led by an industry-experienced management team and supported by a veteran Board of Directors as well as a reputable medical advisory board. Existing investors include ex-CEO’s and CFO’s of publicly traded medical device corporations (Baxter Healthcare, Baxalta, etc.), KOL surgeons from leading universities (Northwestern, NYU, Northshore) and respected angel groups from across the country (Harvard Business School Angels, Gopher Angels, Ann Arbor Angels). We’ve also received $2M of NCI SBIR grants with an opportunity for $4M of follow-on grant funding, providing investors with great leverage. We are now seeking a $10M Series B predominantly to fuel sales growth, with a target closing in Q1 2021.

Check Surgical Innovation Associates’ Dedicated Page

← Older Entries
Newer Entries →